DIN 02509695 — ZOLGENSMA 20000000000000 VG
ZOLGENSMA is a solution of Onasemnogene abeparvovec marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Onasemnogene abeparvovec monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02509695
- Brand name
- ZOLGENSMA
- Active ingredient
- Onasemnogene abeparvovec
- Strength
- 20000000000000 VG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- AAV9 vector-based gene therapy (SMN1 gene replacement)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.